Table II. Outcomes data for prospective randomized controlled trials of prophylactic somatostatin analogues versus placebo for patients undergoing elective pancreatic resection.
| Pancreatic fistula (%) |
Overall morbidity (%) |
Overall mortality (%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Author | Year | N | Placebo | Octreotide | Placebo | Octreotide | Placebo | Octreotide |
| Büchler 51 | 1992 | 246 | 38 | 18 | 55 | 32* | 5.8 | 3.2 |
| Pederzoli 56 | 1994 | 252 | 19 | 9 | 29 | 16* | 3.8 | 1.6 |
| Montorsi 57 | 1995 | 218 | 20 | 9* | 36 | 22* | 5.6 | 8.1 |
| Friess 58 | 1995 | 247 | 22 | 10* | 30 | 16* | 0.8 | 1.6 |
| Lowy 59 | 1997 | 110 | 6 | 12 | 25 | 30 | 0 | 2 |
| Yeo 52 | 2000 | 211 | 11 | 9 | 34 | 40 | 0 | 1 |
| Sarr** 50 | 2003 | 275 | 23 | 24 | 26 | 30 | 1 | 0 |
| Suc 53 | 2004 | 230 | 19 | 17 | 37 | 29 | 7 | 12 |
*p < 0.05 versus corresponding control group. ** this group used vapreotide instead of octreotide.